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B and T cell abnormalities In patients with primary IgA nephropathy.
The in vitro function of B and T cells was studied in 16 patients with
primary IgA nephropathy (PIgA-N). The distribution of OKT3 cells
(total peripheral T cells) and of regulatory Tcell subsets (helper OKT4
and cytotoxic/suppressor OKT8 cells) was evaluated and a testing for
47 HLA-A, B, C, DR. and DQ antigens was carried out in the 16. B
lymphocyte IgA production, after stimulation by pokeweed mitogen in
the presence of T cells from normal donors treated with mitomycin C,
was significantly greater in patients than in controls. T lymphocytes
from patients with PIgA-N were more efficient than T cells from
controls in providing IgA specific helper activity for normal B cells. The
analysis of the individual data showed that the overactivity of B cells
and the T cell operational dysfunction was present in about 50% of the
patients and did not correlate. No numerical imbalance between T
lymphocyte subsets nor any association between lymphocyte behavior,
HLA antigen distribution, and a number of clinical, laboratory, and
immunohistological findings was observed. Our data, therefore, suggest
that PIgA-N is an immunologically heterogeneous disease and that an
IgA-specific B cell overactivity and/or overall IgA-specific T cell helper
activity may be present in some patients.
Anomalies des cellules Bet T chez des malades atteints de nêphropathle
primItive a igA. La fonction in vitro des cellules B et I a été étudiée
chez 16 malades atteints de néphropathie primitive 6 IgA (PIgA-N). La
distribution des cellules OKT3 (cellules T priphériques totales) et des
sous-populations cellulaires régulatrices T (cellules OKT4 helper et
OKT8 cytotoxiques/suppressives) ont été évaluées et un typage pour
47 antigènes HLA-A, B, C, DR, et DQ a 6t6 entrepris chez les 16. La
production d'IgA lymphocytaire B apr6s stimulation par le pokeweed
mitogen en presence de cellules I provenant de donneurs normaux
traités avec de Ia mitomycine C, était significativement plus 6levée chez
les malades que chez les contrôles. Les lymphocytes T de malades
atteints de PIgA-N taient plus efficaces que les cellules T provenant de
contrôles pour fournir une activit IgA helper sp6cifique aux cellules B
normales. L'analyse des données individuelles a montr6 que la
suractivité des cellules B et Ic dysfonctionnement oprationnel
cellulaire T taient presents chez environ 50% des malades et n'Ctaient
pas corrClCs. Aucun dCsCquilibre numCrique entre les sous-populations
lymphocytaires I, ni aucune association entre Ic comportement
lymphocytaire, Ia distribution des antigCnes HLA, et un grand nombre
de donnCes cliniques, biologiques, et immunohistochimiques n'ont etC
observes. Nos donndes suggCrent donc que Ic PIgA-N est une maladie
immunologiquement hCtCrogCne, et qu'une suractivitC cellulaire B a
IgA spCcifique, et/ou une activitC cellulaire T helper IgA spCcifique
pourrait Ctre prCsente chez certains malades.
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Primary IgA nephropathy (PIgA-N), originally described by
Berger and Hinglais in 1968 [1], is the most common primary
glomerulonephritis in southern Europe, Australia, and Japan
[2]. The diagnosis is made when immunofluorescent studies
show that IgA is the only or predominant immunoglobulin in the
glomerular mesangium in the absence of any recognizable
systemic or chronic hepatic disease.
Clinical and histological observations seem to suggest a major
role of IgA in the pathogenesis of the disease. Moreover, in the
last few years, several studies have described a number of
immunological abnormalities in the IgA immune system of
patients with PIgA-N, for example, high serum levels of IgA or
circulating IgA immune complexes [2, 3], an increase in the
number of IgA-bearing B lymphocytes [4] or in the OKT4/-
OKT8 cell ratio [2, 5, 6] or in the number of IgA-specific
helper T cells [7], and, finally, a decrease in specific IgA-
suppressor cells activity [8]. These data, however, have not
always been confirmed.
The major purpose of our study was to evaluate the distribu-
tion of peripheral T lymphocyte subsets and the in vitro
function of B and T cells in patients with PIgA-N. Furthermore,
we investigated the association between the in vitro lymphocyte
behavior and the HLA system of the patients studied. Finally,
a possible correlation between immunological findings and
some clinical and histological data was examined.
Methods
Patients
The subjects of this study were 16 consecutive patients with
PIgA-N and plasma creatinine levels equal to or less than 1.5
mg/dl who were admitted to the Division of Nephrology and
Dialysis of Malpighi Hospital in Bologna, Italy, between
March, 1983, and April, 1984. The patients (eight male and eight
female) ranged in age from 15 to 56 years (mean 31.5). The
diagnosis was assessed by renal biopsy in each patient. Light
and immunofluorescence microscopy were performed in all
cases and electron microscopy in 12. The criteria for the
admission were the presence of predominant mesangial IgA
deposits at the immunofluorescence staining of the renal biopsy
specimens, and the absence of clinical or biological evidence for
a systemic disease (Henoch-Schönlein purpura, systemic lupus
erythematosus) or extrarenal pathology (chronic hepatic dis-
eases). Normal B and T lymphocytes for co-culture experi-
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ments were obtained from 16 healthy volunteers of the staff,
age- and sex-matched (eight male and eight female, age range,
19 to 54 years), with no evidence of renal or systemic disease.
The control group for the study of T lymphocyte subsets
consisted of 23 normal individuals, average age 30, range 17 to
53 years. At the time of the study, none of the patients or
controls were taking any drugs known to alter lymphocyte
number or function.
Methods
Preparation of mononuclear cell suspensions and T- and
B-enriched cell populations. Peripheral mononuclear cell sus-
pensions were obtained from 30 ml of venous heparinized blood
of patients and controls, by Hypaque-Ficoll gradient centrifu-
gation following the BOyum method [9]. Adherent cells were
depleted by incubation in plastic Petri dishes at 37°C for 30 mm.
Mononuclear cells were washed intensively with Hank's solu-
tion and once with RPM! 1640 medium. The last wash was
found to be free of immunoglobulins measured by a fluorimetric
assay (see below). To obtain T- and B-enriched cell popula-
tions, the rosette-forming cells were separated from non-ro-
sette-forming cells by centrifugation on Hypaque-Ficoll gradi-
ent. Cells collected from the interface were used as a B-
enriched cell population. Rosette-forming cells in the bottom of
the gradient, lysed with trisbuffered ammonium chloride and
then washed were used as a T-enriched cell population. This
procedure yielded a B-cell-enriched suspension containing less
than 5% E rosette-forming cells and a 1-cell-enriched suspen-
sion containing 95 to 100% E rosette-forming cells.
Preparation of mitomycin C-treated T lymphocytes. T cells
obtained as described above from the 16 healthy volunteers of
the staff were incubated at a concentration of 1 x 106 cells/ml in
RPM! 1640 medium for 30 mm at 37°C at a concentration of 25
g/1 x 106 cells of mitomycin C (Kyowa Hakko C., Tokyo,
Japan), and then washed thoroughly with the medium. The
findings of Siegal and Siegal [10], Fauci, Pratt, and Whalen [11],
and Kishimoto et al [12] provided the rationale for co-culturing
mitomycin C-treated T cells with B cells in our experiments.
Indeed, the addition of mitomycin-treated human T cells to
peripheral blood lymphocytes or B cells in culture with PWM
has been shown to have an enhancing effect on immunoglobulin
production by B cells in vitro.
Functional assays of B and T cell function. B cell function
was examined in an in vitro assay of immunoglobulin produc-
tion by the use of a helper T cell-dependent activator (PWM) in
cultures containing mixtures of B cells from patients (Bp), or
from normal subjects (Bn), with T cells from normal donors and
treated with mitomycin C (Tnx). To evaluate T cell function, Bn
were stimulated in vitro with PWM in the presence of Tnx and
1 cells from patients with PIgA-N (Tp) or in the presence of Tnx
and T cells from normal subjects (Tn). The amount of IgG and
IgA secreted in the supematant was measured. In brief, tripli-
cate cultures containing four different allogeneic mixtures of 1
and B cells were performed as follows:
A) Bn + PWM + Tnx: immunoglobulin production by PWM-
stimulated normal B cells in the pres-
ence of control T cells pretreated with
mitomycin C.
B) Bp + PWM + Tnx: immunoglobulin production by PWM-
stimulated patient B cells in the pres-
ence of control T cells pretreated with
mitomycin C.
C) Bn + PWM + Tnx + Tn: immunoglobulin production by
PWM-stimulated normal B cells
in the presence of control I cells
pretreated with mitomycin C and
normal T cells.
D) Bn + PWM + Tnx + Tp: immunoglobulin production by
PWM-stimulated normal B cells
in the presence of control I cells
pretreated with mitomycin C
and patient T cells.
T cell and B cell fractions from each patient and control were
isolated as described above. Normal B and T cells and
mitomycin C-pretreated T cells utilized in each co-culture
experiment were pooled from 16 healthy volunteers of the staff.
In experiments B and D, Bp and Tp were cells drawn from
individual patients with PIgA-N without being pooled. To
minimize possible errors of interpretation caused by different
cell co-culture conditions, experiments A and C (normal control
values) were repeated each time tests B and D (values of the
patients studied) were carried out. By the end of the study, we
had done 16 experiments on each type of co-culture (A, B, C,
D). In each experiment, an equal number of each B and T cell
population was cultured at a concentration of 1 x 106 viable
cells/ml. Preparations were 90 to 95% viable, as assessed by the
trypan blue dye exclusion method. The test was performed for
each B- and T-cell-enriched suspension before co-culture ex-
periments were carried out, and repeated immediately after the
7-day co-culture period in every case. Co-culture medium was
RPM! 1640 supplemented with 20% heat-inactivated fetal calf
serum (FCS, Gibco Lab., Paisley, Scotland), 2 mi glutamine
(Gibco), 50 sg/ml streptomycin, and 100 U/mI penicillin. 100
sg/ml of PWM (Gibco) were added and cell cultures were
incubated for 7 days in a humid 5% C02-containing atmosphere
at a temperature of 37°C. The amount of mitogen was selected
from dose-response kinetic studies in five normal controls and
in five patients in whom maximum response was obtained with
the above dose. On day 7 of the cultures, the amount of IgG and
IgA produced by lymphocytes was measured in the supernatant
by a fluorimetric assay (immunofluor procedure for low level
determination, Bio-Rad Lab., Richmond, California, USA)
modified as described previously [13]. Reproducibility of the
method was verified in within-run and day-to-day tests of the
same specimen. The lowest limit of the test was approximately
20 nglml. Culture medium alone (containing 20% FCS) did not
produce any significant background.
Identf1cation of T cell subsets. The distribution of OKT3
cells (total peripheral I cells) and of the regulatory T cell
subsets (helper OKT4 and cytotoxic/suppressor OKT8 cells)
was studied by using monoclonal antibodies directed at human
T lymphocytes termed OKT3, OKT4, and OKT8. An indirect
immunofluorescence assay was used in all the 16 patients and in
23 normal subjects, as described previously [14]. In short, 200
p1 of the mononuclear cell suspension obtained as described
above, at a density of 5 x 106 cells/mi, was first of all incubated
with 5 p1 of OKT3, OKT4, and OKT8 monoclonal antibodies
(Ortho Pharmaceutical Corporation, Raritan, New Jersey,
USA) for 30 mm at 4°C. After being washed twice in cold
phosphate-buffered saline (PBS), the pellet was labelled with 50
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Table I. Clinical and laboratory data at the time of the study
History of Serum Serum
Pa- Age gross Proteinuria creatinine IgA OKT4/ Glomerular
tient years Sex hematuria glday mg/dl mgldl OKT8 deposits* HLA antigens
1 31 M Yes 0,7 1.1 272 1.41 IgA,C3 AlO,A30,B5,B13,DRI,DR7,DQw2
2 25 F Yes 0.1 0.8 679 1.56 IgA,C3,F A9,A29,B35,B17,Cw4,DR5,DRw8,DRw52
3 37 M No 0.5 1.5 543 1.08 lgA,IgG,C3 A2,A9,B17,DR5,DRw52
4 32 M Yes 0.3 1.1 158 1.70 IgA A2,B5,B35,Cw4,DR2,DRw8,DRw52,DQwI
5 25 M Yes 2.5 0.9 177 1.77 IgA,C3,F A2,A29,B13,B40,Cw3,DR5,DR7
6 53 M No 0.1 1.3 219 1.58 IgA,C3 Al,A28,B5,B8,DR5,DR7,DRw52,DQw2
7 27 F Yes 0.1 0.7 258 1.33 IgA,IgG,C3,F A2,Aw33,B16,DR2,DR6,DQwl
8 41 M No 1.2 1.5 292 2.10 IgA,C3 A9,A30,B12,B22,Cw3,DR3,DRw52
9 38 F Yes 0.1 1.0 299 1.36 IgA,IgG,C3 AI,A2,B5,DR2
10 30 F No 0.5 0.9 415 1.17 IgA,C3,F A28,A3,B35,Cw4,DR7,DRw52,DQw2
11 18 F Yes 0.1 0.9 330 1.32 IgA,IgG,C3 A2,A9,B15,B18,Cw2,DR1,DR7,DRw52
12 15 M Yes 1.1 1.0 212 1.44 IgA,C3 A2,B35,CwI,DR1,DR5,DRw52
13 31 F Yes 1.0 0.7 194 1.70 IgA,C3,F AlO,A29,B14,B21,DR2,DR3,DRwS2,DQwI
14 20 F Yes 1.2 0.7 389 1.27 lgA,IgG A9,A31,B7,B15,DR2,DR4,DRw53,DQwI
15 56 F No 0.7 1.1 353 1.50 IgA A2,Bl2,B21,Cw5,DR5,DRw8,DRw52
16 26 M No 2.6 1.2 470 1.07 IgA,IgM,C3,F A2,B5,Bl2,Cw4,DR5,DRw52
* Only immunofluorescence deposits with intensity 2 to 4+ are recorded.
Table 2. Mean values (±sD) of IgG and IgA production in the different in vitro cultures
A B C D
IgG, ng/ml 232.5 107.2 250.9 196.1 306.5 153.1 308.4 163.4
IgA, ng/ml 139.9 72 278.1 121* 136.8 53.7 305.3 145.6*
Abbreviations are: A, Bn + PWM + Tnx; B, Bp + PWM + Tnx; C, Rn + PWM + Tnx + Tn; D, Bn + PWM + Tnx + Tp.
Comparisons were made between mean values of IgG production in experiments B vs. A and in experiments D vs. C.
The same comparisons were repeated for IgA production.
* P < 0.001 (Student's t test).
d of fluoresceinated goat anti-mouse Ig serum (Bionetics Lab.
Prod., Kensington, Maryland, USA) diluted 1:30, at 4°C for 30
mm. After being washed in the same cold medium, a drop of the
lymphocyte suspension was examined using a Leitz Orthoplan
microscope equipped for epifluorescence. Two hundred lym-
phocyte-like cells were counted, monocytes being excluded
from the count following morphological criteria [14]. T cell
subsets were expressed as the percentage of each fluorescent T
cell subset with respect to the total number of mononuclear
cells present in each field.
HLA typing. HLA-A, -B, and -C antigens were determined
by the standard NIH microlymphocyto-toxicity technique [15]
in our 16 Caucasian PIgA-N patients and in 425 Caucasian local
controls. All the subjects were typed for 12 HLA-A (A1,2,3,9,
10,1 l,28,29,30,31,32,w33), 17 HLA-B (B5,7,8,12,13,14,15,16,
17,18,21 ,22,27,35,37,40,w41) and 5 HLA-C (Cwl ,2,3,4,5) using
a panel of 119 well-defined antisera. For each antigen speci-
ficity, two to four antisera were used.
HLA-DR and DQ antigens. Immunoglobulin-bearing B lym-
phocytes were isolated from neuraminidase rosette-forming
cells (T lymphocytes) as described by Longo and Ferrara [16].
Cytotoxicity tests were performed by standard microcytotox-
icity assay [171 in all the 16 IgA-N patients and in 130 Caucasian
local controls. DR1 to DR7, DRw8, DRw52, and DRwS3 were
the DR antigens tested for. In the same patients and controls,
three additional B cell alloantigen systems defined recently as
DQwl, DQw2, and DQw3 were examined. DR-DQ antigens
were determined using a panel of 120 antisera; from 3 to 10
antisera were tested to define each antigen specificity.
Other methods. Serum IgA concentration was estimated by
rate nephelometry (I.C.S. Beckman, Fullerton, California,
USA), and was considered to be high when above 350 mgldl.
Renal biopsy specimens were studied at light, immunofluores-
cence, and electron microscopy as described elsewhere 118].
The intensity of specific fluorescence for IgG, IgA, 1gM, C3,
Clq, and fibrinogen was graded 0 to 4+. Only deposits from 2
to 4+ were considered for this work.
Statistical analysis
All results are expressed as arithmetic means SD or SEM.
The significance of the difference between each group and the
control was tested by unpaired Student's t test and Fisher's
exact test as appropriate. The significance of the frequency
differences of the HLA antigens between control and disease
samples was assessed with contingency tables by x2 after
correction for the number of comparisons made.
Results
The main clinical and laboratory data of the patients studied
are reported in Table 1. All the patients had microscopic
hematuria at the time of the study. A previous history of gross
hematuria was present in ten. Ten patients had a proteinuria of
0.5 g or more per 24 hrs. A serum IgA concentration above 350
mg/dl was observed in six out of 16 cases (37.5%).
Immunoglobulin production in vitro. As shown in Table 2,
PWM-stimulated B lymphocytes from patients with PIgA-N
produced in vitro a significantly higher amount of IgA than B
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Fig. 1. Distribution of individual values of IgA
production in different types of cultures. Bars
represent the mean SD of each group of
experiments. For details, see Results.
lymphocytes from controls (278.1 121 ng/ml versus 139.9
72 SD ng/ml, P < 0.001). To the contrary, no statistically
significant difference in mean IgG synthesis was observed when
B lymphocytes from IgA patients or from controls were stimu-
lated in vitro in identical experimental conditions (250.9 196.1
ng/ml versus 232.5 107.2 SD ng/ml; P, NS).
To test changes in the immunoregulatory role of T cells in
PIgA-N, T lymphocytes from patients or normal subjects were
added to allogeneic normal B cells in co-culture experiments. T
cells from patients with PIgA-N significantly increased the
production of IgA, but not of IgG, by PWM-stimulated B cells
from normal donors (IgA production: 305.3 145.6 ng/ml
versus 136.8 53.7 SD ng!ml; P < 0.001) (Table 2).
The analysis of the individual data demonstrated, however,
that a dual behavior in IgA synthesis was present. In fact, an
increased production of IgA (greater than two standard devia-
tions of the mean of controls) by B lymphocytes from patients
was observed in seven out of 16 cases, and the amount of in
vitro IgA production by allogeneic normal PWM-stimulated B
cells was enhanced by the addition of T cells from nine out of 16
patients (Fig. 1).
T lymphocytes from four out of the seven patients with
enhanced B lymphocyte IgA production and from five out of the
nine patients with normal B lymphocyte IgA production in vitro
were more efficient than T cells from controls in providing
IgA-specific helper activity for normal allogeneic B cells (Fish-
er's exact test: P. NS).
T cell subsets and HLA typing. No alterations in the T cell
subset percentage were found in patients with PIgA-N com-
pared to normal ones (Tables 2 and 3).
In this particular sample, the frequency of HLA antigens in
our PIgA-N patients was similar to the one in the control
population (Table 1).
Immunological and clinical, laboratory or immunohistologi-
cal correlations. No significant correlations were found be-
tween the IgA production in vitro and any of the following: sex,
previous history of gross hematuria, amount of proteinuria,
serum IgA levels, HLA antigens, T cell subset distribution,
type and amount of deposits of immunoglobulins and comple-
ment at immunofluorescence microscopy.
Table 3. Mean percentage values of peripheral T lymphocyte subsets
in patients and in control population*
N
OKT
cells
%
3 OKT4
cells
%
OKT
cells
%
8
OKT4/
OKT8
Controls 23 70.6 1.6 59.9 1.5 39.1 1.7 1.57 0,07
Patients 16 71.4 1.7 53.4 0.9 37.6 1.5 1.45 0.05
* Values are the mean 5EM.
N = number of individuals.
Discussion
A large number of clinical studies have been published in the
last decade concerning the clinical aspects of IgA nephropathy.
Comparatively few works have, on the other hand, been
published about the pathogenesis of the disease. Some recent
findings seem to suggest that an abnormality of the IgA immune
system, possibly genetically mediated, may be responsible for
the appearance of the classic IgA nephropathy.
Egido et al demonstrated in 1983 [19] that PWM-stimulated
peripheral blood mononuclear cells (PBM) from patients with
IgA nephropathy produced in vitro a significantly greater
amount of IgA (but not of IgG and 1gM) than PBM from
controls after 7 days of culture. The same group of authors
demonstrated, in subsequent experiments, that there was aug-
mentation in the activity of IgA-helper T cell and a deficient IgA
specific suppressor T cell function in patients with IgA nephrop-
athy [6]. This observation was consistent with that of Sakai,
Nomoto, and Arimori in 1979 [8]. More recently, Rothschild
and Chatenoud [201 have suggested that a deficient suppressor
T cell function may sometimes exist in this nephropathy.
However, at variance with the report by Sakai, Nomoto, and
Arimori [81, the anomaly of suppressor T cell activity was not
IgA specific. In this study, B and T cell function was examined
separately by different in vitro co-culture experiments in the
presence of PWM and allogeneic normal T cells treated with
mitomycin C (Tnx). In our experience, enriched B cell suspen-
sions from PIgA patients selectively synthetized more IgA than
enriched B cells from controls. The same results have been
simultaneously observed by Hale et al [21] in Australia. Be-
600
400
600
200
400
I
200
A B C D
650 Cagnoli et a!
sides, overall analysis of the data from our groups C and D
points to the presence of an imbalance between IgA specific
helper and suppressor T cell function in patients with PIgA-N.
This imbalance enhances the IgA production by allogeneic
normal B cells. Endoh et al [22] have demonstrated recently
that T cells with receptor for the Fc portion of IgA, that is, Ta
cells, are IgA-specific helper I cells, and Sakai et al [7] have
observed an increase in Ta cells in peripheral blood from
patients with PIgA-N, thus suggesting that an increase in Ta
cells may be responsible for the increased synthesis of IgA in
such patients. The higher IgA production in cultures of PWM-
stimulated PBM in some previous reports may therefore be due
to an increase in Ta cells in those experiments. The possibility
that residual T cells might affect the in vitro synthesis of IgA by
B cell-rich suspension even in our study cannot be completely
ruled out. Our B-cell-enriched suspension, however, contained
only less than 5% E rosette-forming cells, and no correlation
was found between B lymphocyte hyperfunction and abnormal
T lymphocyte behavior of the individual patients. Indeed, the
analysis of the individual data shows an overactivity of B cells
in seven patients and an operational dysfunction of T cells
leading to an exaggerated IgA synthesis in nine out of the 16
patients who were not correlated. The lymphocyte function was
normal in the remaining cases. This observation is consistent
with Egido et al [23] who showed deficient suppressor T cell
function in 40% of patients with PIgA-N, and with Rothschild
and Chatenoud [201 who observed, in a different in vitro assay,
a reduced suppressor T cell function in only a few of the
patients with this disease. Our data, therefore, indicate that two
different and autonomous lymphocyte dysfunctions, that is,
IgA-specific B cell overactivity and overall IgA-specific T cell
helper activity, may be present in some patients with PIgA-N.
Various attempts to demonstrate numerical alterations of B
and T lymphocyte subpopulations and/or an imbalance between
regulatory T cell subsets in PIgA-N provided contrasting re-
sults. Overall percentage of B and T lymphocytes, evaluated by
different procedures, have been found to be constantly normal
[2, 24]. Japanese authors reported an increased number of
circulating IgA-bearing lymphocytes both in patients with
PIgA-N and in members of their families [4, 25], but others have
been unable to confirm those data [2]. In 1981, Chatenoud and
Bach showed an increased OKT4/OKT8 cell ratio in five out
of nine patients studied, mainly due to a decrease in OKT8 T
cell subset [5]. Egido et al [19] observed a significant increase in
the mean values of helper OKT4 cells and D'Amico [2] found
an increased OKT4/OKT8 cell ratio due both to an increase
of OKT4 cells and to a decrease in OKT8 cells. In a previous
study [14], we were not able to demonstrate any imbalance
between T lymphocyte subsets in 12 patients with PIgA-N, and
now we can confirm those findings further in a new, larger
series of patients. The different OKT cell distribution pattern
in the various reports could be due to the different phase of
disease activity, as suggested by Feehally and co-workers [26],
or else it is more likely to be due to its heterogeneity. In any
case, our study confirms, along with others [20], the absence of
any correlation between in vitro lymphocyte functions and the
numerical level of OKT4 and OKT8 cells. This could prob-
ably be accounted for by the functional heterogeneity of these T
lymphocyte subsets [20] or by the few clones of both sets of
cells involved in IgA secretion [6].
The immune response in mice is controlled by genes that are
strongly linked to the genes of the major histocompatibility
complex. Due to the existence of familial IgA nephropathies
[27] and some abnormalities in the immune regulation of the IgA
and in T cell subsets in the relatives of patients with PIgA-N
[19], a genetic basis for the susceptibility of this disease has
been put forward. Some investigators, especially in France, the
United States, and Japan [28—31], have claimed a higher prev-
alence of some HLA-A, -B, and -DR antigens.
In the present series of 16 patients and in an additional 15
cases of PIgA-N (unpublished data), no prevalence of any of the
antigens studied was shown, in accordance with a number of
other reports [32—34]. This is not surprising because the singu-
larly high frequency of HLA antigens in IgA nephropathy varies
from country to country, and the same antigen, DR4, has been
considered the marker of a good or poor prognosis of the
disease in the same country by two Japanese research groups
[30, 31]. It may be that a genetically induced abnormality in the
immune response causes some cases of PIgA-N, but it is likely
that more than one gene exerts influence in determining sus-
ceptibility to the disease, together with different factors in
different populations, as speculated by Richman, Mahoney, and
Fuller in 1979 [29].
Finally, in accordance with others [6, 20, 21], we were unable
to prove any correlation between T and B lymphocyte alter-
ations and a number of clinical, immunohistological, and labo-
ratory parameters, including serum IgA levels.
In conclusion, a functional alteration of B and/or T cells,
which induces an increased production of IgA after PWM
stimulation in vitro, may be present in some patients. These
data corroborate the hypothesis that PIgA-N could be due in
vivo to deposition of IgA immune complexes or aggregates that
probably originate in the migratory lymphocytes from the
secretory tissues in response to stimulation by viral or microbic
antigens [6]. PIgA-N seems, however, to be an immunologically
heterogeneous disorder, and no clear-cut correlations have
been demonstrated between in vitro and in vivo findings.
Further studies are in progress to elucidate the exact role of
these immunological aberrations in the pathogenesis and prog-
nosis of the disease.
Reprint requests to Prof. P. Zucchelli, Divisione di Nefrologia e
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